Thermo Fisher Scientific Inc
TN8
Company Profile
Business description
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Contact
168 Third Avenue
WalthamMA02451
USAT: +1 781 622-1000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
125,000
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,924.20 | 83.70 | 0.95% |
| CAC 40 | 7,915.36 | 78.13 | -0.98% |
| DAX 40 | 23,409.37 | 181.66 | -0.77% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,249.52 | 35.23 | -0.34% |
| HKSE | 25,916.68 | 159.39 | 0.62% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 54,248.39 | 1,519.67 | 2.88% |
| NZX 50 Index | 13,094.37 | 4.46 | -0.03% |
| S&P 500 | 6,795.99 | 55.97 | 0.83% |
| S&P/ASX 200 | 8,692.60 | 90.30 | 1.05% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |